These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 25858358)

  • 21. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
    Famà R; Bomben R; Rasi S; Dal Bo M; Ciardullo C; Monti S; Rossi F; D'Agaro T; Zucchetto A; Gattei V; Gaidano G; Rossi D
    Blood; 2014 Dec; 124(25):3831-3. PubMed ID: 25498455
    [No Abstract]   [Full Text] [Related]  

  • 24. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
    Jain N; O'Brien S
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):851-60, x. PubMed ID: 23915749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
    Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
    Wu J; Zhang M; Liu D
    Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
    Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
    Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
    [No Abstract]   [Full Text] [Related]  

  • 28. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Foluso O; Glick A; Stender M; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of B-cell receptor signalling in B-cell malignancies.
    Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
    J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Wang M; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Nakhoda S; Vistarop A; Wang YL
    Br J Haematol; 2023 Jan; 200(2):137-149. PubMed ID: 36029036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
    Bhatt V; Alejandro L; Michael A; Ganetsky A
    Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
    Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of
    Quinquenel A; Fornecker LM; Letestu R; Ysebaert L; Fleury C; Lazarian G; Dilhuydy MS; Nollet D; Guieze R; Feugier P; Roos-Weil D; Willems L; Michallet AS; Delmer A; Hormigos K; Levy V; Cymbalista F; Baran-Marszak F;
    Blood; 2019 Aug; 134(7):641-644. PubMed ID: 31243043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
    Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
    Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ
    Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.